Medline (NASDAQ:MDLN) Raised to Buy at Wall Street Zen

Medline (NASDAQ:MDLN) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other analysts have also issued reports about the stock. Royal Bank Of Canada lowered their price target on shares of Medline from $53.00 to $46.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. William Blair reissued an “outperform” rating on shares of Medline in a research report on Wednesday, September 23rd. Tigress Financial lowered their target price on shares of Medline from $62.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. BMO Capital Markets restated an “outperform” rating and issued a $47.00 price target on shares of Medline in a report on Thursday, August 6th. Finally, Barclays lowered their target price on shares of Medline from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 9th. Twenty-three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.08.

Medline Price Performance

MDLN stock opened at $39.64 on Friday. The stock has a market cap of $52.12 billion and a price-to-earnings ratio of 90.09. The business has a 50 day moving average price of $34.78 and a 200 day moving average price of $39.48. Medline has a fifty-two week low of $31.37 and a fifty-two week high of $50.88. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.32 by $0.12. The business had revenue of $7.86 billion during the quarter. Equities research analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Medline

In other news, major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the transaction, the insider owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. This trade represents a 11.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 7,948,676 shares of company stock worth $281,805,137. 0.81% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after acquiring an additional 254 shares during the period. Covestor Ltd grew its stake in shares of Medline by 31.8% during the 3rd quarter. Covestor Ltd now owns 1,953 shares of the company’s stock worth $68,000 after purchasing an additional 471 shares during the period. NewEdge Advisors LLC lifted its stake in Medline by 100.0% during the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 475 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after purchasing an additional 487 shares during the period. Finally, Whipplewood Advisors LLC purchased a new position in shares of Medline during the 1st quarter worth about $30,000.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, beating the $0.32 consensus estimate, with revenue of $7.86 billion. Shares gapped higher following the earnings report. Medline shares gap up following strong earnings
• Positive Sentiment: Analyst target increases add to the bullish outlook: UBS raised its target to $49 and maintained a Buy rating; Citi raised its target to $47 and kept Buy; and Leerink Partners lifted its target to $46 with an Outperform rating. UBS ratings Citi ratings Leerink Partners ratings
• Positive Sentiment: BTIG reaffirmed its Buy rating with a $55 target, while Barclays also assigned a Buy rating, adding to the favorable analyst sentiment. BTIG ratings Barclays rating
• Positive Sentiment: Medline plans price increases in 2027 to offset inflation, which could help protect revenue and profitability if customers accept the higher prices. Pricing plans and Q3 results

Medline Company Profile

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations.

The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations.

Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.